Can a new formulation make arthritis shots less painful?
NCT ID NCT05913817
Summary
This study looked at whether switching patients to a higher concentration version of the drug adalimumab (brand name SIMLANDI™) causes less injection site pain than the standard version. It involved 324 Canadian adults with conditions like Crohn's disease, rheumatoid arthritis, or psoriasis who were already using adalimumab. Researchers tracked their pain levels, treatment adherence, and satisfaction over six months after the switch.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
JAMP Pharma Corporation
Montreal, Quebec, J4B 5H3, Canada
Conditions
Explore the condition pages connected to this study.